Expression analysis of liver-specific circulating microRNAs in HCV-induced hepatocellular Carcinoma in Egyptian patients

References

• Schöler N, Langer C, Döhner H, Buske C, Kuchenbauer F. Serum microRNAs as a novel class of biomarkers: a comprehensive review of literature. Exp Hematol. 2010;38(12):1126–130. doi:10.1016/j.exphem.2010.10.004.
   PubMed Web of Science ®Google Scholar
• Lee RC, Feinbaum RL, Ambros V. The C. elegans Heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-4. Cell. 1993;75(5):843–854. doi:10.1016/0092-8674(93)90529-Y.
   PubMed Web of Science ®Google Scholar
• Barger JF, Rahman MA, Jackson D, Acunzo M, Nana-Sinkam SP. Extracellular miRNAs as biomarkers in cancer. Food Chem Toxicol. 2016;98:66–72. doi:10.1016/j.fct.2016.06.010.
   PubMed Web of Science ®Google Scholar
• Aqeilan RI, Calin GA, Croce CM. miR-15a and miR-16-1 in cancer: discovery, function, and future perspectives. Cell Death Differ. 2010;17:215–220. doi:10.1038/cdd.2009.69.
   PubMed Web of Science ®Google Scholar
• Tinkle CL, Haas-Kogan D. Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics. 2012;6:207–219.
   PubMedGoogle Scholar
• Ding J, Wang H. Multiple interactive factors in hepatocarcinogenesis. Cancer Lett. 2014;346(1):17–23. doi:10.1016/j.canlet.2013.12.024.
   PubMed Web of Science ®Google Scholar
• El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118–1127. doi:10.1056/NEJMra1001683.
   PubMed Web of Science ®Google Scholar
• Kandeel A, Genedy M, El-Refai S, Funk AL, Fontanet A, Talaat M. The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment. Liver Int. 2017;37(1):45–53. doi:10.1111/liv.13186.
   PubMed Web of Science ®Google Scholar
• Khalifa RH, Labib DA, Kamel MA, Shahin RMH, Bahgat DMR, Riad NM, El Khateeb E, El-Deeb AM, Hassan M. Role of ApoB-516C/T promoter gene polymorphism in the risk of Hepatitis C virus infection in Egyptian patients and in gender susceptibility. J Med Virol. 2017;89(9):1584–1589. doi:10.1002/jmv.24815.
   PubMed Web of Science ®Google Scholar
• Elgharably A, Gomaa AI, Crossey MM, Norsworthy PJ, Waked I, Taylor-Robinson SD. Hepatitis C in Egypt- past, present, and future. Int J of Gen Med. 2017;10:1–6. doi:10.2147/IJGM.S119301.
   PubMed Web of Science ®Google Scholar
• Cabibbo G, Reig M, Gadaleta-Caldarola G, Galati G, Lombardi G, Mazza G, Marzi L, Saitta C, Nault JC, Sacco R. The calm before the storm: a report from the International Liver Cancer Association congress 2015- part 1. Future Oncol. 2016;12(3):281–284. doi:10.2217/fon.15.323.
   PubMedGoogle Scholar
• Aubé C, Oberti F, Lonjon J, Pageaux G, Seror O, N'Kontchou G, Rode A, Radenne S, Cassinotto C, Vergniol J, et al. EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice. Liver Int. 2017;37(10):1515–1525. doi:10.1111/liv.13429.
   PubMed Web of Science ®Google Scholar
• Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18(10):997–1006. doi:10.1038/cr.2008.282.
   PubMed Web of Science ®Google Scholar
• Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol. 2009;112(1):55–59. doi:10.1016/j.ygyno.2008.08.036.
   PubMed Web of Science ®Google Scholar
• Ho AS, Huang X, Cao H, Christman-Skieller C, Bennewith K, Le QT, Koong AC. Circulating miR-210 as a novel hypoxia marker in pancreatic Cancer. Transl Oncol. 2010;3(2):109–113. doi:10.1593/tlo.09256.
   PubMed Web of Science ®Google Scholar
• Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010;127(1):118–126. doi:10.1002/ijc.25007.
   PubMed Web of Science ®Google Scholar
• Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol. 2011;45(4):355–360. doi:10.1097/MCG.0b013e3181f18ac2.
   PubMed Web of Science ®Google Scholar
• Ge W, Yu DC, Li QG, Chen X, Zhang CY, Ding YT. Expression of serum miR-16, let-7f, and miR-21 in patients with hepatocellular carcinoma and their clinical significances. Clin Lab. 2014;60(3):427–434.
   PubMed Web of Science ®Google Scholar
• Huang XH, Wang Q, Chen JS, Fu XH, Chen XL, Chen LZ, Li W, Bi J, Zhang LJ, Fu Q, et al. Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma: miR-338 is downregulated. Hepatol Res. 2009;39(8):786–794. doi:10.1111/j.1872-034X.2009.00502.x.
   PubMed Web of Science ®Google Scholar
• Miao HL, Lei CJ, Qiu ZD, Liu ZK, Li R, Bao ST, Li MY. MicroRNA-520c-3p inhibits hepatocellular carcinoma cell proliferation and invasion through induction of cell apoptosis by targeting glypican-3. Hepatol Res. 2014;44(3):338–348. doi:10.1111/hepr.12121.
   PubMed Web of Science ®Google Scholar
• Yu L, Ding GF, He C, Sun L, Jiang Y, Zhu L. MicroRNA-424 is down-regulated in hepatocellular carcinoma and suppresses cell migration and invasion through c-Myb. PLoS One 2014;9(3):e91661. doi:10.1371/journal.pone.0091661.
   PubMed Web of Science ®Google Scholar
• Shen J, Wang Q, Gurvich I, Remotti H, Santella RM. Evaluating normalization approaches for the better identification of aberrant microRNAs associated with hepatocellular carcinoma. Hepatoma Res. 2016;2:305–315. doi:10.20517/2394-5079.2016.28.
   PubMedGoogle Scholar
• Shen Q, Cicinnati VR, Zhang X, Iacob S, Weber F, Sotiropoulos GC, Radtke A, Lu M, Paul A, Gerken G, et al. Role of microRNA-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma. Mol Cancer. 2010;9:227. doi:10.1186/1476-4598-9-227.
   PubMed Web of Science ®Google Scholar
• Li J, Wang Y, Yu W, Chen J, Luo J. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem Biophys Res Commun. 2011;406 (1):70–73. doi:10.1016/j.bbrc.2011.01.111.
   PubMed Web of Science ®Google Scholar
• Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011;39(16):7223–7233. doi:10.1093/nar/gkr254.
   PubMed Web of Science ®Google Scholar
• Bi Q, Tang S, Xia L, Du R, Fan R, Gao L, Jin J, Liang S, Chen Z, Xu G, et al. Ectopic expression of miR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF. PLoS One 2012;7(6):e40169. doi:10.1371/journal.pone.0040169.
   PubMed Web of Science ®Google Scholar
• Gu W, Li X, Wang J. miR-139 regulates the proliferation and invasion of hepatocellular carcinoma through the WNT/TCF-4 pathway. Oncol Rep. 2014;31(1):397–404. doi:10.3892/or.2013.2831.
   PubMed Web of Science ®Google Scholar
• Wang Y, Hu C, Cheng J, Chen B, Ke Q, Lv Z, Wu J, Zhou Y. MicroRNA-145 suppresses hepatocellular carcinoma by targeting IRS1 and its downstream Akt signaling. Biochem Biophys Res Commun. 2014;446(4):1255–1260. doi:10.1016/j.bbrc.2014.03.107.
   PubMed Web of Science ®Google Scholar
• Diaz G, Melis M, Tice A, Kleiner DE, Mishra L, Zamboni F, Farci P. Identification of microRNAs specifically expressed in hepatitis C virus-associated hepatocellular carcinoma. Int J Cancer. 2013;133(4):816–824. doi:10.1002/ijc.28075.
   PubMed Web of Science ®Google Scholar
• Kawaguchi T, Komatsu S, Ichikawa D, Tsujiura M, Takeshita H, Hirajima S, Miyamae M, Okajima W, Ohashi T, Imamura T, et al. Circulating microRNAs: a next-generation clinical biomarker for digestive system cancers. Int J Mol Sci. 2016;17(9): pii: E1459. doi:10.3390/ijms17091459.
   Web of Science ®Google Scholar